Article - BioPharm International

ADVERTISEMENT

Article

Final Word: The Case for Flexible Manufacturing Capacity

August 1, 2007

The mounting threats of pandemic influenza, bioterrorism, and emerging infectious diseases continue to be the focus of research programs and funding initiatives, not only within governmental agencies, but also universities, private research firms, and commercial manufacturing entities. With all of these efforts, however, the question of manufacturing capacity and the ability to respond to pandemic and emerging threats continues to be a major concern.

Outsourcing: Managing Your Contractor Relationship—A Smart Investment

August 1, 2007

Companies need to avoid operating in a manner that is inconsistent with the priorities established in the strategic sourcing decision.

China Today: Biopharmaceutical Exports

August 1, 2007

In 2006, China exported a total of $890 million in biologics to other countries—a 30.61% increase, compared with the previous year.

From the Editor: After Zheng

August 1, 2007

The corruption of China's food and drug sectors is not limited to one man. Likewise, real reform will require the efforts of many.

Patents: Patent Strategies for Biotechnology Enterprises

August 1, 2007

Companies in the biotech industry typically require one or several partners as they complete the product development cycle.

Biotech Manufacturers Face Competition from "Similar" Follow-Ons

August 1, 2007

The main testing and regulatory provisions of the FOB legislation reflect multiple trade-offs between the demands of innovators and generics firms.

China Today: Next Steps Toward Globalization

July 1, 2007

Most Chinese biopharmaceuticals are relatively small and there are not enough of them to sustain a robust services sector.

From the Editor: Learning from the Diethylene Glycol Tragedies

July 1, 2007

Quality guidelines are only as good as their implementation.

Vendor Notes: The Biovest AutovaxID: Enabling the Promise of Personalized Medicine

July 1, 2007

The AutovaxID is a self-contained, completely enclosed, fully automated hollow fiber bioreactor that permits rapid, efficient scale up of patient-derived cells. It is based on hollow fiber bioreactor technology and is an ideal system for high-density cell culture and the production of monoclonal antibodies or other therapeutic proteins.

ADVERTISEMENT

ADVERTISEMENT

Click here